If you want to understand Lilly today, read its incretin patents as a single estate, not a pile of separate inventions. The 2025 grants, read in order, lay out a deliberate structure.
The foundation is the molecule. Incretins are the gut hormones — GIP and GLP-1 — that govern blood sugar and appetite, and Lilly's lead drug hits both. Grant US12252524B2 covers GIP/GLP1 co-agonist compounds, including formulation and dosing detail. That's the core deed.
The next layer is method of use. US12295987B2 covers a method of using a GIP/GLP1 co-agonist for diabetes. A method patent protects the act of treating a condition with the drug — a separate claim from the molecule itself, with its own life.
The third layer is breadth across analogs. US12365716B2 covers incretin analogs and their uses — extending protection beyond the exact lead molecule to a family of related ones. That's how you stop a competitor from sidestepping with a near-copy.
Why does the layering matter to a reader sizing up the franchise? Because exclusivity isn't a single date. The compound, the method, and the analogs can expire at different times, and a challenger has to clear every live claim. Stagger them and the protected core keeps moving forward.
The short version: Lilly's incretin estate is a building, not a brick — compound on the ground floor, method above it, analogs filling out the structure. The 2025 grants are the company adding floors. Understanding that is the difference between seeing a looming cliff and seeing an actively defended franchise.